BioVex announced that it has commenced recruiting patients for its OPTiM (OncoVEX Pivotal Trial in Melanoma) Phase 3 study of OncoVEX (GM-CSF) in previously treated patients with unresectable Stage III and Stage IV melanoma. This trial is a multi-national, open label, randomized study enrolling 360 patients to assess the efficacy and safety of treatment with OncoVEX (GM-CSF) as compared to subcutaneously administered GM-CSF. Patients will have received at least one prior therapy for active disease which includes any type of therapy including investigational drugs.
OncoVEX is a first-in-class oncolytic, or cancer destroying virus technology, designed to replicate and spread within solid tumors, causing the death of cancer cells, while stimulating the immune system to destroy un-injected metastatic deposits.
For more information call (781) 376-4900 or visit www.oncovexgmcsf.com.